This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder

Arthur Rifkin, MD; Frederic Quitkin, MD; Donald F. Klein, MD

Arch Gen Psychiatry. 1975;32(5):672-674.

Abstract
Akinesia is an extrapyramidal behavioral side-effect of antipsychotic medication characterized by a lessening of spontaneity, paucity of gestures, diminished conversation, and apathy. It can be easily confused with depression, demoralization, and residual schizophrenic defect. Studies of the value of maintenance antiparkinson medication usually overlook this common syndrome. We present eight case histories to illustrate this condition.

Author Affiliations
From the Long Island Jewish-Hillside Medical Center, Hillside Division, PO Box 38, Glen Oaks, New York.

Footnotes
Accepted for publication Feb 10, 1975.

Reprint requests to the Long Island Jewish-Hillside Medical Center, Hillside Division, Glen Oaks, NY 11004 (Dr. Rifkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chronic Restlessness With Antipsychotics
Bratti et al.
Am. J. Psychiatry 2007;164:1648-1654.
FULL TEXT  

Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers
Artaloytia et al.
Am. J. Psychiatry 2006;163:488-493.
ABSTRACT | FULL TEXT  

Atypical Antipsychotics in Parkinson-Sensitive Populations
Friedman and Fernandez
J Geriatr Psychiatry Neurol 2002;15:156-170.
ABSTRACT  

Suicide and schizophrenia
Siris
J Psychopharmacol 2001;15:127-135.
ABSTRACT  

Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Siris
Am. J. Psychiatry 2000;157:1379-1389.
ABSTRACT | FULL TEXT  

Differentiating Primary From Secondary Negative Symptoms in Schizophrenia: A Study of Neuroleptic-Naive Patients Before and After Treatment
Peralta et al.
Am. J. Psychiatry 2000;157:1461-1466.
ABSTRACT | FULL TEXT  

Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol
Tollefson et al.
Arch Gen Psychiatry 1998;55:250-258.
ABSTRACT | FULL TEXT  

Maintenance Imipramine Therapy for Secondary Depression in Schizophrenia: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1994;51:109-115.
ABSTRACT  

Lithium-Induced Delirium With Therapeutic Serum Lithium Levels: A Case Report
Brown and Rosen
J Geriatr Psychiatry Neurol 1992;5:53-55.
ABSTRACT  

Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose
McEvoy et al.
Arch Gen Psychiatry 1991;48:739-745.
ABSTRACT  

A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten et al.
Arch Gen Psychiatry 1990;47:754-758.
ABSTRACT  

Norepinephrine in Acute Exacerbations of Chronic Schizophrenia: Negative Symptoms Revisited
van Kammen et al.
Arch Gen Psychiatry 1990;47:161-168.
ABSTRACT  

Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT  

The Positive-Negative Distinction in Drug-Free Schizophrenic Patients: Stability, Response to Neuroleptics, and Prognostic Significance
Kay and Singh
Arch Gen Psychiatry 1989;46:711-718.
ABSTRACT  

Who Should Receive Clozapine?
Marder and Van Putten
Arch Gen Psychiatry 1988;45:865-867.
ABSTRACT  

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger
Arch Gen Psychiatry 1987;44:660-669.
ABSTRACT  

Adjunctive Imipramine in the Treatment of Postpsychotic Depression: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1987;44:533-539.
ABSTRACT  

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT  

Postpsychotic Depressive Symptoms in Hospitalized Schizophrenic Patients
Siris et al.
Arch Gen Psychiatry 1981;38:1122-1123.
ABSTRACT  

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride
Hogarty et al.
Arch Gen Psychiatry 1979;36:1283-1294.
ABSTRACT  

Predicting Drug-Free Improvement in Schizophrenic Psychosis
Marder et al.
Arch Gen Psychiatry 1979;36:1080-1085.
ABSTRACT  

Psychiatry
Freedman
JAMA 1979;241:1373-1375.
ABSTRACT  

Use of Antidepressant Drugs in Schizophrenia
Siris et al.
Arch Gen Psychiatry 1978;35:1368-1377.
ABSTRACT  

'Akinetic Depression' in Schizophrenia
Van Putten and May
Arch Gen Psychiatry 1978;35:1101-1107.
ABSTRACT  

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics
Quitkin et al.
Arch Gen Psychiatry 1978;35:889-892.
ABSTRACT  

Catatonic Stupor and Neuroleptic Drugs
Weinberger and Wyatt
JAMA 1978;239:1846-1846.
ABSTRACT  

Are Prophylactic Antiparkinson Drugs Necessary? A Controlled Study of Procyclidine Withdrawal
Rifkin et al.
Arch Gen Psychiatry 1978;35:483-489.
ABSTRACT  

Fluphenazine Decanoate, Oral Fluphenazine, and Placebo in Treatment of Remitted Schizophrenics: II. Rating Scale Data
Rifkin et al.
Arch Gen Psychiatry 1977;34:1215-1219.
ABSTRACT  

Extrapyramidal Side Effects in Chlorpromazine Recipients: Emergence According to Benztropine Prophylaxis
Swett et al.
Arch Gen Psychiatry 1977;34:942-943.
ABSTRACT  

Catatonic Reactions to High-Potency Neuroleptic Drugs
Gelenberg and Mandel
Arch Gen Psychiatry 1977;34:947-950.
ABSTRACT  

Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally, and Placebo in Remitted Schizophrenics: I. Relapse Rates After One Year
Rifkin et al.
Arch Gen Psychiatry 1977;34:43-47.
ABSTRACT